Cantor Fitzgerald initiated coverage on IMV with a new price target
$IMV
Pharmaceuticals and Biotechnology
Health Care
Cantor Fitzgerald initiated coverage of IMV with a rating of Overweight and set a new price target of $4.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/22/2021 | $4.00 | Overweight | Cantor Fitzgerald |
| 7/23/2021 | $14.00 | Overweight | Wells Fargo |
- First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with Committed Backlog of $218 Million, Including $187 Million in HRZN Commitments - - Declares Regular Monthly Distributions Totaling $0.33 per Share - FARMINGTON, Conn., May 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and
IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Thursday, March 16, 2023, at 8:00 a.m. ET to discuss the company's 2022 fourth quarter and fiscal year-end financial and operational results. Financial analysts are invited to join the conference call by registering at this link prior the call to receive their individual dial-in information. Other interested parties will be able to access the live audio webcast at this link: https://ir.imv-inc.com/events-and-presentations. The webcast will be
IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced its financial and operational results and provided an update for the third quarter ended September 30, 2022. "IMV worked diligently to deliver on our clinical goals in the third quarter. We restructured the business to facilitate the achievement of these objectives and remain on track to present meaningful clinical data early next year," said Andrew Hall, Chief Executive Officer of IMV. "We expect 2023 to be a potentially transformative year for IMV, w
IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that Nasdaq, in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, has in exercising its discretion determined to delist the Company's common shares as a result of the Company's announcement on May 1, 2023 that the Nova Scotia Supreme Court had issued an initial order (the "Initial Order") granting the Company and its subsidiaries prote
- First Quarter 2023 Net Investment Income per Share of $0.46; NAV per Share of $11.34 - - Debt Portfolio Yield of 16.3% - - Grew Portfolio Year over Year by 39% to $715 Million - - Horizon Platform Ends Quarter with Committed Backlog of $218 Million, Including $187 Million in HRZN Commitments - - Declares Regular Monthly Distributions Totaling $0.33 per Share - FARMINGTON, Conn., May 2, 2023 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN", "Horizon" or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and
IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that the Nova Scotia Supreme Court (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries protection under the Companies' Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the "CCAA"). The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code. After a careful review of available
Cantor Fitzgerald initiated coverage of IMV with a rating of Overweight and set a new price target of $4.00
Wells Fargo resumed coverage of IMV with a rating of Overweight and set a new price target of $14.00
SC 13G - IMV Inc. (0001734768) (Subject)
SC 13G/A - IMV Inc. (0001734768) (Subject)
SC 13G/A - IMV Inc. (0001734768) (Subject)
15-12G - IMV Inc. (0001734768) (Filer)
F-10POS - IMV Inc. (0001734768) (Filer)
F-10POS - IMV Inc. (0001734768) (Filer)
Reorganization enhances organizational focus on strategic priorities Clinical update on DLBCL patients in Phase 2B VITALIZE trial to be provided in September Appointment of Dr. Saman Maleki to Board of Directors Brittany Davison promoted to Chief Accounting Officer IMV Inc. (NASDAQ:IMV, TSX:IMV) ("IMV" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced a strategic reorganization together with the appointment of Dr. Saman Maleki to the Company's Board of Directors and promotion of Brittany Davison to Chief Accounting Officer. "We have m
IMV Inc. ("IMV" or the "Company") (NASDAQ:IMV, TSX:IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the voting results from its annual and special meeting of shareholders held on June 29, 2022 (the "Meeting"). Based on the votes received, all resolutions were accepted, including the election of directors, for whom details of the votes are as follows: Name of nominee Votes FOR % of votes FOR Votes Withheld % of votes Withheld Michael Bailey 27,525,895 99.11% 246,171 0.89% Brittany Davison 27,582,627 99.32% 189,439 0.68%
IMV Inc. (NASDAQ:IMV, TSX:IMV), ("IMV" or "the Company"), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid tumors and blood cancers, announced today that its Board of Directors has appointed Andrew Hall to the role of Chief Executive Office and Director of the Board, effective January 1, 2022. "On behalf of the Board and the Company, I congratulate Andrew on his appointment to the Chief Executive Officer role. Over the last 5 months, Andrew has demonstrated strong leadership and refocused the Company to capitalize on its strengths in immuno-oncology, as well as a strategy designed to fully realize IMV's clear poten
Upgrades According to Colliers Securities, the prior rating for Centerspace (NYSE:CSR) was changed from Neutral to Buy. In the first quarter, Centerspace showed an EPS of $1.07, compared to $0.98 from the year-ago quarter. The stock has a 52-week-high of $96.84 and a 52-week-low of $51.26. At the end of the last trading period, Centerspace closed at $56.87. According to Bernstein, the prior rating for Roper Technologies Inc (NYSE:ROP) was changed from Market Perform to Outperform. Roper Techs earned $3.90 in the first quarter, compared to $3.77 in the year-ago quarter. At the moment, the stock has a 52-week-high of $481.65 and a 52-week-low of $357.25. Roper Techs closed at $458.63 at the
HC Wainwright & Co. analyst Joseph Pantginis downgrades IMV (NASDAQ:IMV) from Buy to Neutral.
IMV Inc. (the "Company" or "IMV") (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical Company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced today that the Nova Scotia Supreme Court (the "Court") has issued an initial order (the "Initial Order") granting the Company and its subsidiaries protection under the Companies' Creditors Arrangement Act (R.S.C., 1985, c. C-36) (the "CCAA"). The Company will seek the recognition of the Initial Order in the United States by filing a petition commencing proceedings under the Chapter 15 of the United States Bankruptcy Code.After a careful review of available opt